Candel Therapeutics, Inc. (CADL) Cash Flow Statement
Candel Therapeutics, Inc. (CADL) generated -$56.0M of operating cash flow over the twelve months to 2026-06-30, spent $1.3M on capital expenditure and had free cash flow of -$57.3M, according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
CADLCandel Therapeutics, Inc.Follow CADL — free
—
Price chart with a free account
- Market cap
- 614.4M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 5 Nov, in 12 days
| Line | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|
| Operating cash flow | -22.2 | -31.4 | -34.2 | -27.0 | -38.3 | -56.0 | |
| Capital expenditure | 1.8 | 1.3 | 0.5 | 0.0 | 0.6 | -1.3 | |
| Free cash flow | -24.1 | -32.7 | -34.7 | -27.0 | -38.9 | -57.3 | |
| Stock-based compensation | 3.0 | 2.3 | 3.1 | 5.3 | 3.8 | — |
USD millions · SEC XBRL
Candel Therapeutics, Inc. — questions
- What is Candel Therapeutics, Inc.'s operating cash flow?
- -$56.0M over the twelve months to 2026-06-30.
- How much does Candel Therapeutics, Inc. spend on capital expenditure?
- $1.3M over the twelve months to 2026-06-30.
- What is Candel Therapeutics, Inc.'s free cash flow?
- -$57.3M over the twelve months to 2026-06-30: operating cash flow minus capital expenditure.
Every figure on this page comes from Candel Therapeutics, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.